SCHEMBL5447183

SCHEMBL5447183

CCNC(=O)N1CCC(S(=O)(=O)c2ccc(Nc3ncc(/C=C/c4ccc5nc(N)sc5c4)cn3)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 13/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPT P10636 2/20 0.35
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
GPR183 P32249 1/20 0.35
VDR P11473 1/20 0.35
GFER P55789 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447186 1.00 NAMPT (0.38) NAMPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5439151 0.85 NAMPT (0.44) NAMPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5439153 0.85 NAMPT (0.44) NAMPTCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5433438 0.84 ALDH1A1 (0.41) NAMPTCYP3A4CYP2D6ALDH1A1LMNA
SCHEMBL5433443 0.84 ALDH1A1 (0.41) NAMPTCYP3A4CYP2D6ALDH1A1LMNA
SCHEMBL14490601 0.84 ALDH1A1 (0.42) CYP3A4CYP2D6ALDH1A1LMNAHSD17B10
SCHEMBL5437730 0.82 ALDH1A1 (0.39) NAMPTCYP2D6ALDH1A1LMNAHSD17B10
SCHEMBL5437734 0.82 ALDH1A1 (0.39) NAMPTCYP2D6ALDH1A1LMNAHSD17B10
SCHEMBL5447048 0.80 SYK (0.40) CYP1A2CYP3A4CYP2D6CYP2C9ALDH1A1
SCHEMBL5447069 0.80 SYK (0.40) CYP1A2CYP3A4CYP2D6CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR NAMPT 2364/4885CYP1A2 1726/4885CYP3A4 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.